Heart transplant in a factor VIII‐deficient patient with a high‐titre inhibitor: perioperative management using high‐dose continuous infusion factor VIII and recombinant factor VIIa

Four years prior to transplantation, a 14‐year‐old boy with severe haemophilia A and a high‐responding factor VIII (FVIII) inhibitor developed an anteroseptal myocardial infarct while receiving high doses of an activated prothrombin complex concentrate (PCC). Cardiac transplantation was required for survival because of the ensuing cardiomyopathy. At surgery, the patient’s inhibitor titre was 1.8 Bethesda units (BU). High‐dose bolus therapy, followed by a continuous infusion of FVIII provided excellent operative and initial postoperative haemostasis without additional blood‐product support. Once anamnaesis developed on day 6 postoperatively, recombinant factor VIIa (rFVIIa) therapy was initiated. Haemostasis remained excellent, except for the transient increase in chest‐tube bleeding that was noted on day 7. ɛ‐aminocaproic acid was added and haemostasis was re‐established. On day 15, rFVIIa was replaced with alternate day infusions of prothrombin complex concentrates (PCCs). On day 21 following the transplant, the patient was discharged, remaining on daily FVIII immune tolerance and thrice‐weekly PCC prophylaxis. He remains well 24 months after transplant with an inhibitor titre of 39 BU. This paper describes the second case of cardiac transplantation complicated by haemophilia and an inhibitor, and discusses preoperative planning and operative and postsurgical haemostasis management.

[1]  J. Vermylen,et al.  Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor , 1999, Thrombosis and Haemostasis.

[2]  W. Muntean,et al.  Recombinant Factor VIIa Does not Induce Hypercoagulability In Vitro , 1999, Thrombosis and Haemostasis.

[3]  M. Levi,et al.  Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. , 1998, The Netherlands journal of medicine.

[4]  J. Vermylen,et al.  Optimal care of inhibitor patients during surgery , 1998, European journal of haematology. Supplementum.

[5]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[6]  C. Kessler,et al.  Safety, efficacy and lessons from continuous infusion with rFVIIa , 1998 .

[7]  J. Lusher,et al.  Clinical experience with recombinant factor VIIa. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  S. Schulman Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  C. Rothschild,et al.  Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.

[10]  P. Brill,et al.  Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A , 1997, Pediatric Radiology.

[11]  E. Scheibel,et al.  Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. , 1996, Haemostasis.

[12]  E. Berntorp Properties of factor IX concentrates. , 1995, Acta Haematologica.

[13]  J. Scott,et al.  Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia a patients with inhibitors , 1994, American journal of hematology.

[14]  J. Lusher,et al.  Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations. , 1994, Seminars in hematology.

[15]  P. Lanzkowsky,et al.  Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor. , 1993, The American journal of pediatric hematology/oncology.

[16]  J. Lusher Prediction and management of adverse events associated with the use of factor IX complex concentrates. , 1993, Seminars in hematology.

[17]  U. Hedner Factor VIIa in the treatment of haemophilia. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[18]  D. Siegel,et al.  Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. , 1988, The American journal of medicine.

[19]  B. Glader,et al.  Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. , 1984, Pediatrics.

[20]  D. Doyle,et al.  Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies. , 1984, The Journal of thoracic and cardiovascular surgery.